To print: Select File and then Print from your browser's menu


Title: Innovative Long-Acting Contraceptive Product Mirena(R) Approved in Japan
 "Innovative Long-Acting Contraceptive Product Mirena(R) Approved in Japan"


BERLIN, GERMANY -- January 30, 2007 -- The Japanese Ministry of Health, Labour and Welfare (MHLW), has granted marketing approval for Bayer Schering Pharma's long-acting intrauterine contraceptive system Mirena®. The product is expected to be launched in Japan in April 2007 under the trade name Mirena® 52 mg and will significantly enhance the choice of methods of contraception available to women in Japan. "In Japan there has been a limited choice in convenient, reliable and reversible long-acting contraception" said Phil Smits, Head of Women's Healthcare at Bayer Schering Pharma AG. "We are delighted that with Mirena® we can offer women in Japan an innovative long-acting method for contraception. With the Mirena® launch in Japan we will further strengthen our leading position on the Japanese market and grow our worldwide leadership in female contraception". The approval is based on broad experience from international studies as well as a Japanese study program, including a large clinical trial with more than 400 Japanese women. Until now, Mirena® has been used by more than 10 million women worldwide and is registered in more than 100 countries. With the approval in Japan, Mirena® is now available in all major pharmaceutical markets worldwide. About Mirena® Mirena®, a levonorgestrel-releasing intrauterine contraceptive system (IUS), is marketed in many countries throughout the world. Mirena® offers advantages to other birth control options, in particular compared to conventional intrauterine devices (IUDs). In addition to preventing pregnancy effectively over a period of five years, many women experience shorter, lighter and less painful periods while using Mirena®. Mirena® does not contain estrogen. Instead, Mirena® delivers a low dose of the progestin levonorgestrel (approx. 20 microgram/day) to the lining of the uterus and thereby provides desired local effects and minimizes undesired systemic effects. The insertion and removal of the intrauterine system Mirena® takes only a few minutes. It can easily be done by a trained health care professional in a doctor's office on an outpatient basis. Once Mirena® is removed, fertility is rapidly restored. SOURCE: Bayer Health Care






Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.



Go back

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 2009 P\S\L Consulting Group Inc.
All rights reserved.